| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 15.05. | Acurx Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update | 63 | PR Newswire | STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class... ► Artikel lesen | |
| 02.05. | Acurx Pharmaceuticals, Inc.: Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference | 52 | PR Newswire | STATEN ISLAND, N.Y., May 2, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics... ► Artikel lesen | |
| 29.03. | Acurx Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 21.03. | Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV | 325 | Newsfile | Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel... ► Artikel lesen | |
| 19.03. | Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 18.03. | Acurx Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Acurx Pharmaceuticals, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.03. | Acurx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 18.03. | Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update | 503 | PR Newswire | STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class... ► Artikel lesen | |
| 15.03. | Acurx Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 15.03. | Acurx Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.02. | Acurx Pharmaceuticals, Inc.: Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development | 221 | PR Newswire | As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)
As anticipated, an End of Phase... ► Artikel lesen | |
| 29.01. | Acurx Pharmaceuticals, Inc.: Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients | 192 | PR Newswire | In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection
Further... ► Artikel lesen | |
| 17.01. | Acurx Pharmaceuticals, Inc.: Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients | 187 | PR Newswire | Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of C. difficile in... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 5.344 |
| GAMESTOP | 3.502 |
| NEL | 3.426 |
| NVIDIA | 3.289 |
| EVOTEC | 3.191 |
| BAYER | 2.443 |
| BYD | 1.790 |
| PLUG POWER | 1.708 |
| VOLKSWAGEN | 1.331 |
| DEUTSCHE LUFTHANSA | 1.233 |
| RHEINMETALL | 1.169 |
| DEUTSCHE TELEKOM | 1.104 |
| BIONTECH | 1.093 |
| ALLIANZ | 1.061 |
| SUPER MICRO COMPUTER | 1.055 |
| AIXTRON SE | 877 |
| DEUTSCHE BANK | 857 |
| SIEMENS ENERGY | 848 |
| COMMERZBANK | 817 |
| RWE | 806 |
| BASF | 782 |
| THYSSENKRUPP | 744 |
| TESLA | 708 |
| MERCEDES-BENZ | 690 |
| BARRICK GOLD | 640 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
